Literature DB >> 1301962

Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers.

J Alcocer-Varela1, D Aleman-Hoey, D Alarcon-Segovia.   

Abstract

We examined cerebrospinal fluid (CSF) samples from 12 patients with SLE and active central nervous system (CNS) involvement for their levels of the following cytokines: interleukin-1 (IL-1) by means of two different assays--the IL-1 responsive murine cell line LBRM 33-la5 and an ELISA for IL-1 alpha; IL-2 by means of the CTLL cell line responsive to it; and interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) both determined by a specific ELISA. We found that SLE CSF had significantly higher levels of IL-1 and IL-6 than did those obtained at surgery from eight controls without inflammatory neurologic disease. IL-2 and TNF were not detectable in any of the CSF samples. We also studied the status of activation in CSF T cells using monoclonal antibodies against early (anti-IL-2R (CD25) and anti-transferrin (CD71)), late (anti-T10) and very late (anti-VLA-1) activation antigens, and found increased percentages of T10-bearing (18 +/- 2 vs 3 +/- 0.7%) and VLA-1-bearing T cells (12 +/- 2 vs 0.7 +/- 0.2%) in SLE patients as compared to controls (both P < 0.01). Levels of IL-1 and IL-6 correlated with T10 and those of IL-1 correlated also with VLA-1. Markers of early T-cell activation did not differ in SLE and control CSF. Because of these findings we analysed the effect of recombinant IL-1, IL-6 or normal CSF on normal T cells and found that they did not induce the expression of activation markers.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1301962     DOI: 10.1177/096120339200100209

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  23 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

Review 2.  Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus.

Authors:  Meggan Mackay
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

3.  Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus.

Authors:  E Svenungsson; M Andersson; L Brundin; R van Vollenhoven; M Khademi; A Tarkowski; D Greitz; M Dahlström; I Lundberg; L Klareskog; T Olsson
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

4.  Differential serum cytokine profile in patients with systemic lupus erythematosus and posterior reversible encephalopathy syndrome.

Authors:  J Merayo-Chalico; A Barrera-Vargas; G Juárez-Vega; J Alcocer-Varela; A Arauz; D Gómez-Martín
Journal:  Clin Exp Immunol       Date:  2018-01-16       Impact factor: 4.330

Review 5.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

Review 6.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

Review 7.  Cytokine networks in systemic lupus erythematosus.

Authors:  Hooi-Ming Lee; Hidehiko Sugino; Norihiro Nishimoto
Journal:  J Biomed Biotechnol       Date:  2010-04-15

Review 8.  Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Akiko Kobayashi; Hisashi Yamanaka
Journal:  J Biomed Biotechnol       Date:  2010-06-29

9.  Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases.

Authors:  M al-Janadi; S al-Balla; A al-Dalaan; S Raziuddin
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

10.  Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus.

Authors:  L J Jara; L Irigoyen; M J Ortiz; B Zazueta; G Bravo; L R Espinoza
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.